Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2012-01-02 Capital/Financing Update
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Bilan semestriel du contrat de liquidité Innate Pharma avec la société Natixis Securities
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ INNATE PHARMA AVEC LA SOCIÉTÉ NATIXIS SECURITIES" (Semi-annual balance sheet of the liquidity contract) and is dated January 2, 2012, reporting figures as of December 31, 2011. This is a periodic report detailing the status of a liquidity agreement, which is a specific financial arrangement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR) which focuses on operational results. It is a specific regulatory disclosure related to market making/liquidity provision. Given the provided definitions, this type of specific financial disclosure, which is not a standard earnings report or a general regulatory filing (RNS), fits best under a category related to specific financial updates or disclosures. Since it details the status of a financial contract periodically, and doesn't fit perfectly into the main financial reports (10-K, IR, ER), it is closest to a specialized financial disclosure. However, looking closely at the options, none perfectly match 'Liquidity Contract Balance Sheet'. It is a formal, periodic financial disclosure. If it were a general regulatory announcement not covered elsewhere, RNS would apply. If it were related to capital structure changes, CAP might apply, but this is about maintaining market liquidity. Given its nature as a formal, periodic financial statement/update that isn't a standard quarterly/annual report, and lacking a specific 'Liquidity Report' code, it is most appropriately classified as a general Regulatory Filing (RNS) or potentially a specialized financial update. Since it is a formal, periodic disclosure required by market rules, RNS (Regulatory Filings - general fallback) is the most suitable general category among the choices, as it is a specific regulatory disclosure that doesn't map to the other detailed financial reports.
2012-01-02 French
Half-year report on Innate Pharma's liquidity contract with Natixis Securities
Capital/Financing Update Classification · 99% confidence The document is titled "HALF-YEAR REPORT ON INNATE PHARMA'S LIQUIDITY CONTRACT WITH NATIXIS SECURITIES" and provides specific figures related to a liquidity account as of December 31, 2011. This content relates to financial reporting for a period shorter than a full year (half-year). This strongly suggests an Interim/Quarterly Report (IR). While it focuses on a specific contract, the context of reporting period-end figures aligns best with the comprehensive reporting category for non-annual periods. It is not a general Earnings Release (ER) which is usually just highlights, nor is it a full Annual Report (10-K). It is a specific financial disclosure for an interim period.
2012-01-02 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce sa participation au Salon Actionaria qui se tiendra au Palais des Congrès de Paris les 18 et 19 novembre 2011
Report Publication Announcement Classification · 99% confidence The document is a press release dated November 4, 2011, announcing that Innate Pharma will participate in the 'Salon Actionaria' (an investor conference/show) on November 18 and 19, 2011. It details the company's presence (stand number) and the schedule for the CEO's presentation. This is an announcement about a future event where the company will interact with investors, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a presentation document (IP). Since it is an announcement related to investor engagement and future meetings, it most closely aligns with general investor relations communication. Given the options, it is not a specific financial report, management change, or transaction. It is best classified as a general announcement related to investor activities, which falls under the broad 'Regulatory Filings' (RNS) category as a fallback for non-standard investor communications, or potentially related to AGM/Shareholder events, but since it's a trade show, RNS is the most appropriate catch-all for this type of corporate event announcement.
2011-11-04 French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its participation in Actionaria, a forum dedicated to meeting with individual investors, on November 18 & 19, in Paris
Regulatory Filings Classification · 95% confidence The document is a press release dated November 4, 2011, announcing the company's participation in an investor forum called 'Actionaria' on November 18 & 19. It details the CEO's presentation time and provides general company information and contact details for investors. This type of announcement, which informs the market about upcoming investor engagement events (like conferences or forums) rather than releasing periodic financial results (ER, IR) or official statutory reports (10-K, AR), fits best under the general category of investor relations communication. Since there is no specific category for 'Investor Event Announcement,' and it is not a transcript (CT), a presentation (IP), or a formal regulatory filing about a specific event outcome (like DVA or DIV), it is classified as a general Regulatory Filing (RNS) as a catch-all for non-standard investor communications, although it is very close to an Investor Presentation announcement, but it is announcing attendance, not the presentation content itself. Given the options, RNS is the most appropriate fallback for a general corporate/investor relations announcement that doesn't fit a more specific category like ER or IP.
2011-11-04 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce son chiffre d’affaires pour les neufs premiers mois de l'année 2011 et fait le point sur sa trésorerie
Earnings Release Classification · 95% confidence The document is a press release from Innate Pharma announcing its revenue and cash position for the first nine months of 2011. It provides specific financial data (revenue figures, cash position, and debt) for the period ending September 30, 2011. While it contains financial data, it is an initial announcement of quarterly/periodical results rather than a full interim report (which would be a more comprehensive document). Therefore, it fits the definition of an Earnings Release (ER). 9M 2011
2011-11-04 French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its turnover for the first nine months of 2011 and updates on its cash position
Earnings Release Classification · 100% confidence The document is a press release announcing financial results (turnover and cash position) for the first nine months of 2011. It provides key highlights and financial tables but is not a full interim report (which would be more comprehensive). According to the definitions, an initial announcement of quarterly/periodical financial results is classified as an Earnings Release (ER). 9M 2011
2011-11-04 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.